Large-cell immunoblastic lymphoma

Summary

Large-cell immunoblastic lymphoma (MONDO:0022037) is a cancer and 1 clinical trial. A subtype of non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	large-cell immunoblastic lymphoma
Mondo ID	MONDO:0022037
MeSH	D016400
UMLS	C0079746
MedGen	86955
GARD	0008219
Is cancer (heuristic)	yes

Also known as: Diffuse Immunoblastic Lymphosarcoma · Diffuse Immunoblastic Lymphosarcomas · Diffuse non-Hodgkin lymphoma, immunoblastic · Diffuse non-Hodgkin’s immunoblastic (diffuse) lymphoma · Diffuse non-Hodgkin’s lymphoma, immunoblastic · Diffuse non-Hodgkin’s lymphoma, immunoblastic (clinical) · Immunoblastic Large Cell Lymphoma · IMMUNOBLASTIC LARGE LYMPHOMA · Immunoblastic Large-Cell Lymphoma · Immunoblastic Large-Cell Lymphomas · Immunoblastic Lymphoma, Large-Cell · Immunoblastic Lymphomas, Large-Cell · Immunoblastic Lymphosarcoma, Diffuse · Immunoblastic Lymphosarcomas, Diffuse · Immunoblastic malignant lymphoma - large cell · Immunoblastic Sarcoma · Immunoblastic Sarcomas · Immunoblastoma · Immunoblastomas · Large Cell Immunoblastic Lymphoma (+21 more)

Disease family

This is a subtype of non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma › large-cell immunoblastic lymphoma

Related subtypes (9): lymphoblastic lymphoma, lymphosarcoma, acute lymphoblastic leukemia, lymphoma, non-Hodgkin, familial, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, lung non-Hodgkin lymphoma, ocular adnexal lymphoma, gastric non-hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00329030	PHASE3	COMPLETED	Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin’s Lymphoma (BMTCTN0401)